• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Eleven science stories likely to make big news in 2023
As the COVID-19 pandemic enters its fourth year as a global health emergency, researchers will continue pushing to help make the disease manageable and ordinary. They will track hundreds of subvariants of Omicron, the highly transmissible but seemingly less lethal strain of SARSCoV-2 that dominated in 2022. Virologists will watch the virus’ evolution this year to see whether it has finally slowed or a more dangerous variant pops up, evading much of the immunity that humanity has built up to previous ones. Vaccine researchers hope to develop new shots that provide broad protection against a variety of coronaviruses.  Ano...
Source: ScienceNOW - January 4, 2023 Category: Science Source Type: news

What to Know About the Monkeypox Drug TPOXX —And Why It ’ s So Hard to Get
Monkeypox, which federal officials declared a public health emergency on August 4, is not as contagious as the other ongoing public health emergency in the U.S.: COVID-19. Monkeypox primarily spreads through contact with infected skin lesions. Theoretically, containing monkeypox should therefore be more feasible, as long as testing, vaccines, and treatments are accessible. But in reality, the rollouts of all three approaches have faced major challenges. Getting the antiviral drug tecovirimat, also known as TPOXX, is particularly difficult. Here’s what to know about the antiviral drug treatment TPOXX. What is TPOXX? T...
Source: TIME: Health - August 9, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate monkeypox Source Type: news

We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?
At my animal hospital in upstate New York, an epicenter of the U.S. tick epidemic, my dog Fawn lets out a whimper as the veterinarian injects her with her annual Lyme disease shot. I roll my eyes. She doesn’t know how good she has it. The injection means that if a tick bites her (and in rural New York, a tick always does), the creepy crawly will feast on dog blood that’s been supercharged with a Lyme bacteria-killing substance, and Lyme disease won’t be transmitted to Fawn. I wish I could be shot up with that superpower. Currently, there is no human vaccine for Lyme disease—even though more than two...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized Disease feature Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with IMBRUVICA® remai...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fight Aging! Newsletter, August 24th 2020
We report that electrical stimulation (ES) stimulation of post-stroke aged rats led to an improved functional recovery of spatial long-term memory (T-maze), but not on the rotating pole or the inclined plane, both tests requiring complex sensorimotor skills. Surprisingly, ES had a detrimental effect on the asymmetric sensorimotor deficit. Histologically, there was a robust increase in the number of doublecortin-positive cells in the dentate gyrus and SVZ of the infarcted hemisphere and the presence of a considerable number of neurons expressing tubulin beta III in the infarcted area. Among the genes that were unique...
Source: Fight Aging! - August 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Coronavirus Vaccine: Here Are The Latest Developments
(CNN) — While coronavirus keeps spreading and killing with impunity, the world waits for a vaccine that could quash the pandemic. But details and timelines keep shifting. Here’s the latest on where we stand in the race for a vaccine: When will a Covid-19 vaccine be available to the public? No one’s sure yet, but the target is sometime in early 2021. Vaccines in development around the world are in various stages of testing. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he’s confident one of the vaccine candidates will be proven safe and effective by th...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 8, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Closures Covid-19 Boston, MA Health Healthcare Status Coronavirus Coronavirus Vaccine Moderna Therapeutics Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s milestone mar...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid
In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication in vitro showed median inhibitory concentrations (IC50) of 13.87 ± 1.09 μM and 33.33 ± 1.13 μM in Vero and A549 cells, respectively; without showing any cytotoxic effect in both cell lines (median cytotoxic concentration (CC50)> 1,000 μM). Moreover, ATA protected both cell types from ZIKV-induced cytopathic effect (CPE) and apoptosis in a time- and concentration-dependent manner. In addition, pre-treatment of Vero cells with ATA for up to 72 h also...
Source: Frontiers in Microbiology - April 11, 2019 Category: Microbiology Source Type: research

Influenza A Virus Infection Damages Zebrafish Skeletal Muscle and Exacerbates Disease in Zebrafish Modeling Duchenne Muscular Dystrophy
DISCUSSION Here, we investigated the effects of an infectious disease on skeletal muscle tissue alone and in combination with a genetic muscle disease. We found that human IAV can infect zebrafish muscle fibers and cause fiber damage via loss of sarcolemma integrity and/or loss of ECM adhesion external to the sarcolemma. Additionally, we showed that molecular and cellular markers of inflammation are present in muscle tissue in response to IAV infection. Finally, we showed that an infectious disease in combination with a genetic muscle disease greatly worsens the severity of muscle tissue degeneration. Taken together, our r...
Source: PLOS Currents Muscular Dystrophy - October 25, 2017 Category: Neurology Authors: Clarissa Henry Source Type: research

Fight Aging! Newsletter, May 8th 2017
This report captures the state of the research community in a nutshell: progress in the sense that ever more scientists are willing to make the treatment of aging the explicit goal of their research, but, unfortunately, there is still a long way to go in improving the nature of that research. It is still near entirely made up of projects that cannot possibly produce a robust and large impact on human life span. The only course of action likely to extend life by decades in the near future is implementation of the SENS vision for rejuvenation therapies - to repair the molecular damage that causes aging. Everything else on th...
Source: Fight Aging! - May 7, 2017 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Mother ’s Milk and the Environment: Might Chemical Exposures Impair Lactation?
New mothers who quit breastfeeding earlier than they had wanted often chalk it up to not being able to produce enough milk. But a handful of researchers are exploring whether certain environmental exposures may affect some women’s ability to lactate.© Tony Anderson/Getty Images Lactation support includes teaching women techniques to breastfeed and build their milk supply, as well as reassuring them of their ability to nourish their infants.© Phanie/Alamy Stock Photo Education and counseling have been important tools in boosting breastfeeding rates, after decades of marketing mess...
Source: EHP Research - January 2, 2017 Category: Environmental Health Authors: Web Admin Tags: News Focus January 2017 Source Type: research

Why Science Doesn't Need Mice
A recent editorial called "Why Science Needs Female Mice" by the New York Times Editorial Review Board relies on a new study published in Nature Neuroscience by Robert Sorge and his colleagues titled "Different immune cells mediate mechanical pain hypersensitivity in male and female mice." The abstract for this essay reads: "A large and rapidly increasing body of evidence indicates that microglia-to-neuron signaling is essential for chronic pain hypersensitivity. Using multiple approaches, we found that microglia are not required for mechanical pain hypersensitivity in female mice; female mice achieved similar levels of p...
Source: Science - The Huffington Post - July 21, 2015 Category: Science Source Type: news

Evaluation of a non-invasive, inhalational challenge method for rabies vaccine potency assay.
The objective of this study was to evaluate the intranasal route of challenge as a modification to the NIH test to reduce animal pain and suffering until harmonized requirements for in vitro testing of rabies vaccines are developed. Results confirm the intranasal route is an effective route of rabies challenge in mice. However, a valid challenge requires the use of a more concentrated inoculum, in comparison to the intracranial method. PMID: 23557669 [PubMed - in process]
Source: Journal of Virological Methods - May 23, 2013 Category: Virology Authors: Lewis CE, Reising MM, Fry AM, Conrad SK, Siev D, Gatewood DM, Hermann JR Tags: J Virol Methods Source Type: research

PhRMA Report: Over 5400 Medicines in Development and 70% are First in Class
According to report released by PhRMA, companies have more than 5,400 medicines in development globally, and more than 70% of therapies in the pipeline are potentially first-in-class and could offer patients new treatment options, and a notable number of potential therapies target diseases with limited treatment options such as ALS and rare diseases.  A breakdown of their report offers insight into the various medicines in development for different diseases and populations.    Older Americans  America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditi...
Source: Policy and Medicine - April 24, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs